Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Prior treatment

• Known or suspected to be allergic to the investigational drug or any of its components;
• Accepting other investigational drugs upon enrollment, or within 5 biological half-lives of the drug at enrollment, or within 30 days after its last administration, whichever is longer;
• Those who have used any radioactive therapy medication within 90 days before investigational drug administration, or have received any radioactive diagnostic medication within 3 days before investigational drug administration;
• Plan to arrange surgery and other invasive interventions within 2 days after the injection of the investigational drug；
• Ongoing toxicity \>grade l from previous standard or investigational therapies；

Other illness

• Planned androgen deprivation therapies use, any therapeutic intervention for the prostate cancer and use of folate supplements during the study;
• Patients with active infections during screening;

Other

• Those who have no guarantee of being able to lie down quietly in the examination cabin during a PET examination, or those who suffer from claustrophobia and cannot cooperate in a PET examination:
• Other situations where the researchers believe that the subject is not suitable for inclusion in this study.

• Patients with pathologically confirmed prostate cancer;
• Age range from 18 to 75 years old (including 18 and 75 years old);
• ECOG score of 0 or 1;
• Expected life ≥ 6 months；
• The subjects agree to take effective contraceptive measures during the study period and for at least three months after the diug administration;
• The subjects are able to maintain good communication with the researchers；understand and follow the requirements of this study and sign an informed consent form before the start of relevant research operations.